Zacks: Analysts Expect NewLink Genetics Corporation (NLNK) to Post -$0.80 EPS

Equities analysts expect that NewLink Genetics Corporation (NASDAQ:NLNK) will post earnings of ($0.80) per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for NewLink Genetics Corporation’s earnings, with the lowest EPS estimate coming in at ($0.87) and the highest estimate coming in at ($0.75). NewLink Genetics Corporation reported earnings of ($0.54) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 48.1%. The firm is expected to report its next earnings results on Tuesday, November 7th.

On average, analysts expect that NewLink Genetics Corporation will report full year earnings of ($2.79) per share for the current fiscal year, with EPS estimates ranging from ($3.05) to ($2.64). For the next financial year, analysts expect that the company will post earnings of ($2.48) per share, with EPS estimates ranging from ($3.29) to ($1.71). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow NewLink Genetics Corporation.

NewLink Genetics Corporation (NASDAQ:NLNK) last announced its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.21. The business had revenue of $10.37 million for the quarter, compared to analysts’ expectations of $2.65 million. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%.

Several research analysts recently issued reports on the company. Cantor Fitzgerald reaffirmed a “buy” rating and set a $26.00 target price on shares of NewLink Genetics Corporation in a research report on Friday, September 8th. ValuEngine upgraded NewLink Genetics Corporation from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 7th. Zacks Investment Research upgraded NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a research note on Saturday, July 29th. Stifel Nicolaus boosted their price target on NewLink Genetics Corporation from $14.00 to $29.00 and gave the company a “buy” rating in a research note on Monday, September 11th. Finally, Jefferies Group LLC upgraded NewLink Genetics Corporation from a “hold” rating to a “buy” rating and boosted their price target for the company from $7.00 to $26.00 in a research note on Friday, September 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $24.17.

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in NewLink Genetics Corporation by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 959,883 shares of the biotechnology company’s stock valued at $23,134,000 after purchasing an additional 51,013 shares during the last quarter. Columbus Circle Investors grew its stake in NewLink Genetics Corporation by 72.5% during the 2nd quarter. Columbus Circle Investors now owns 591,765 shares of the biotechnology company’s stock valued at $4,349,000 after purchasing an additional 248,724 shares during the last quarter. State Street Corp grew its stake in NewLink Genetics Corporation by 1.2% during the 2nd quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock valued at $2,875,000 after purchasing an additional 4,630 shares during the last quarter. Northern Trust Corp grew its stake in NewLink Genetics Corporation by 4.0% during the 2nd quarter. Northern Trust Corp now owns 298,738 shares of the biotechnology company’s stock valued at $2,195,000 after purchasing an additional 11,532 shares during the last quarter. Finally, Driehaus Capital Management LLC purchased a new stake in NewLink Genetics Corporation during the 1st quarter valued at about $5,127,000. Institutional investors and hedge funds own 54.78% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Expect NewLink Genetics Corporation (NLNK) to Post -$0.80 EPS” was posted by Week Herald and is owned by of Week Herald. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://weekherald.com/2017/09/18/zacks-analysts-expect-newlink-genetics-corporation-nlnk-to-post-0-80-eps.html.

Shares of NewLink Genetics Corporation (NLNK) traded down 4.42% on Friday, reaching $12.11. The company’s stock had a trading volume of 1,760,926 shares. NewLink Genetics Corporation has a 12-month low of $5.90 and a 12-month high of $25.17. The stock’s market cap is $356.29 million. The firm has a 50 day moving average price of $8.51 and a 200-day moving average price of $12.83.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Get a free copy of the Zacks research report on NewLink Genetics Corporation (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply